Full video transcriptClick to expand
Auto-generated transcript of @noneyabusin3zz's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Hello, welcome back to date 10 of taking extra dial. It's already pretty late into the night. I'm about to go to bed
- 0:05So cheers
- 0:07Lately I've been feeling like I have a tummy ache my tummy's been hurting really bad
- 0:12But yeah, I'm so pretty sore from Pilates
- 0:14Which is nice bed and get to do it today because of my tummy
- 0:17But we'll see if we can try to do it tomorrow
- 0:20Thank you guys. Have a good night
Estradiol GI side effects on day 10: what the science says
Quick answer
The creator is on day 10 of estradiol therapy, likely oral given the GI complaints, and reports abdominal discomfort they tentatively attribute to a co-administered medication described as 'prep,' possibly PrEP. Early GI symptoms with oral estradiol are well-documented and generally transient, but concurrent use of tenofovir-based PrEP adds a plausible second source of gastrointestinal irritation. Neither symptom pattern is medically alarming at this stage, though symptom persistence beyond two to four weeks warrants prescriber follow-up.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Estradiol GI side effects on day 10: what the science says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Cardiovascular Safety of Testosterone-Replacement Therapy
TRAVERSE trial anchor for cardiovascular-safety discussions in appropriately diagnosed men.
PubMed
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
Guideline anchor for diagnosis, monitoring, contraindications, and appropriate TRT framing.
PubMed
Understanding weight gain at menopause
Background source for body-composition and weight-change discussions around menopause.
PubMed
Management of obesity in menopause
Current source for menopause-specific obesity management framing.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Estradiol GI side effects on day 10: what the science says should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.
Claim path
Keep researching this testosterone and trt video claims cluster
Best for searchers turning TRT social claims into a safer lab-backed provider discussion.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Estradiol GI side effects on day 10: what the science says" from Sonora. We read the clip as a TRT social video fact-checks claim about Testosterone, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator is on day 10 of estradiol therapy, likely oral given the GI complaints, and reports abdominal discomfort they tentatively attribute to a co-administered medication described as 'prep,' possibly PrEP.
The reason this review is not generic is the source wording and the canonical claim label "trt day 10 of taking estradiol my stomach has been hurting since." In this clip, the useful excerpt is: "Hello, welcome back to date 10 of taking extra dial." That wording changes the review because it points to Testosterone evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Cardiovascular Safety of Testosterone-Replacement Therapy (2023), Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline (2010), and Functional testosterone deficiency in aging men: Clinical impact, diagnostic pathways, and treatment strategies (2026), plus the creator's own wording. Testosterone decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The creator is on day 10 of estradiol therapy, likely oral given the GI complaints, and reports abdominal discomfort they tentatively attribute to a co-administered medication described as 'prep,' possibly PrEP.
FormBlends verdict
Testosterone evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator is on day 10 of estradiol therapy, likely oral given the GI complaints, and reports abdominal discomfort they tentatively attribute to a co-administered medication described as 'prep,' possibly PrEP. Early GI symptoms with oral estradiol are well-documented and generally transient, but concurrent use of tenofovir-based PrEP adds a plausible second source of gastrointestinal irritation. Neither symptom pattern is medically alarming at this stage, though symptom persistence beyond two to four weeks warrants prescriber follow-up.
- Oral estradiol undergoes first-pass liver metabolism, which irritates the GI tract in some users during the first few weeks; symptoms typically resolve with continued use.
- Tenofovir-based PrEP has nausea and abdominal discomfort listed as primary early side effects in the landmark iPrEx trial (Grant et al., 2012, NEJM), making the co-administration a plausible contributor to GI symptoms.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Oral estradiol undergoes first-pass liver metabolism, which irritates the GI tract in some users during the first few weeks; symptoms typically resolve with continued use.
- Tenofovir-based PrEP has nausea and abdominal discomfort listed as primary early side effects in the landmark iPrEx trial (Grant et al., 2012, NEJM), making the co-administration a plausible contributor to GI symptoms.
- Shieh et al. (2021, JAIDS) found no clinically significant suppression of estradiol levels in transgender women using tenofovir-based PrEP, though the evidence base remains limited.
- Transdermal estradiol (gel, patch) bypasses first-pass metabolism and tends to produce fewer GI side effects than oral formulations; switching routes is a provider-guided option.
- GI symptoms lasting beyond two to four weeks into a new hormone regimen, or severe enough to repeatedly affect daily activity, warrant a follow-up message or appointment with the prescribing clinician.
- This video is categorized under TRT on the platform, which is clinically inaccurate. Estradiol-based feminizing hormone therapy and testosterone replacement therapy have different pharmacology, monitoring requirements, and risk profiles and should not share a content category.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @noneyabusin3zz actually say?
Not much, honestly, and that's not a criticism. This is a low-stakes check-in video. The creator says they're on day 10 of taking estradiol, they have a stomach ache that started the night before, and they suspect it might be related to "the prep" they're taking alongside their estrogen. They skipped Pilates because of the discomfort and are heading to bed. No dosage claims, no miracle promises, no medical advice to others.
The word "extra dial" in the transcript is a phonetic transcription error from auto-captioning. They clearly mean estradiol, the primary estrogen used in feminizing hormone therapy. Worth noting because these transcription errors sometimes get screenshotted and misread out of context.
Does the science back this up?
The claim that GI discomfort can occur when starting estradiol, especially oral forms, is well-supported. This isn't controversial territory.
Oral estradiol is metabolized through the liver via first-pass metabolism, which can irritate the GI tract in some people during the early weeks of use. A 2019 review by Streed et al. in the Annals of Internal Medicine noted that GI side effects are among the more commonly reported early complaints with oral hormone therapy in transgender women, though they tend to be mild and transient.
The creator also mentions taking something alongside the estradiol, referring to it as "prep." If they mean PrEP (pre-exposure prophylaxis for HIV, typically tenofovir-based), that's a relevant detail. Tenofovir disoproxil fumarate, a common PrEP component, has documented GI side effects including nausea and abdominal discomfort, particularly in the first few weeks. A 2012 study by Grant et al. in the New England Journal of Medicine flagged nausea as the most frequently reported early side effect in PrEP users. The combination of two medications each capable of causing GI upset on their own makes the stomach ache entirely plausible.
What did they get wrong (or right)?
They got the self-awareness right. Attributing the stomach pain to a medication rather than panicking or ignoring it is reasonable health behavior. They're not diagnosing themselves or telling anyone else what to do.
What's missing, not wrong exactly, is any mention of checking in with a provider. Ten days into a new hormone regimen with GI symptoms that are bad enough to cancel exercise is worth a message to whoever is prescribing. Not because this is alarming, most early GI symptoms from estradiol resolve on their own, but because persistent pain can occasionally signal something unrelated that gets written off as a medication side effect.
The video is also categorized here under TRT (testosterone replacement therapy), which is incorrect. Estradiol is not testosterone. Feminizing hormone therapy and TRT are distinct clinical categories with different goals, monitoring protocols, and risk profiles. That's a platform categorization issue, not the creator's error, but it matters for anyone using these tags to find relevant health information.
What should you actually know?
GI discomfort in the first weeks of oral estradiol is common and usually temporary. If it persists beyond a few weeks or worsens significantly, that's a conversation for whoever manages your hormones, not something to push through silently.
Route of administration matters here. Transdermal estradiol (patches, gels) bypasses first-pass liver metabolism entirely, which tends to reduce GI side effects. Some people switch routes specifically for this reason. That's a clinical decision, not a DIY one, but it's worth knowing the option exists if oral estradiol keeps causing problems.
If the creator is indeed taking PrEP alongside estradiol, some formulations interact mildly with hormone levels, though current evidence does not suggest tenofovir-based PrEP significantly disrupts estradiol pharmacokinetics at standard doses. A 2021 paper by Shieh et al. in the Journal of Acquired Immune Deficiency Syndromes examined this specifically in transgender women and found no clinically meaningful estradiol suppression from PrEP use, though they noted the research base remains thin.
Anyone starting a new hormone regimen should have baseline labs and follow-up monitoring scheduled. This is standard of care, not optional, and a regulated telehealth platform should be building this in from day one.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Sonora · TikTok creator
1.4K views on this video
Day 10 of taking Estradiol! My stomach has been hurting since yesterday night. It might be the prep I’m taking along side my estrogen. Night night and see you for tomorrow 🌙 💤 #trans #lgbtq #transfemme
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about oral estradiol undergoes first-pass liver metabolism,?
Oral estradiol undergoes first-pass liver metabolism, which irritates the GI tract in some users during the first few weeks; symptoms typically resolve with continued use.
What does the video say about tenofovir-based prep has nausea?
Tenofovir-based PrEP has nausea and abdominal discomfort listed as primary early side effects in the landmark iPrEx trial (Grant et al., 2012, NEJM), making the co-administration a plausible contributor to GI symptoms.
What does the video say about shieh et al. (2021, jaids) found no clinically significant suppression?
Shieh et al. (2021, JAIDS) found no clinically significant suppression of estradiol levels in transgender women using tenofovir-based PrEP, though the evidence base remains limited.
What does the video say about transdermal estradiol (gel, patch) bypasses first-pass metabolism?
Transdermal estradiol (gel, patch) bypasses first-pass metabolism and tends to produce fewer GI side effects than oral formulations; switching routes is a provider-guided option.
What does the video say about gi symptoms lasting beyond two to four weeks into a?
GI symptoms lasting beyond two to four weeks into a new hormone regimen, or severe enough to repeatedly affect daily activity, warrant a follow-up message or appointment with the prescribing clinician.
What does the video say about this video?
This video is categorized under TRT on the platform, which is clinically inaccurate. Estradiol-based feminizing hormone therapy and testosterone replacement therapy have different pharmacology, monitoring requirements, and risk profiles and should not share a content category.
Not medical advice. This video was made by Sonora, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.